XILAPLUS® / XILAPLUS® AF

0

ESPGHAN 2023

Noventure will attend the 55th Annual Meeting of the European Society for Paediatric Gastroenterology, Hepatology and Nutrition (ESPGHAN), taking place in Vienna & Online, from May 17th to 23rd, 2023 Arrange a meeting with us to learn more about our products and license availability in the different countries. Meet us at our Stand #33! Contact us: https://noventure.com/contact-us

Read more

Launch of TASECTAN® AF in Finland and Sweden

Following the launch of TASECTAN® AF in Denmark in August, Pharmaforce has just marketed this product also in Finland (September) and Sweden (October). Last April, Noventure granted Pharmaforce exclusive distribution right for TASECTAN® AF in the Nordic markets. TASECTAN® AF is intended to restore the physiological functions of the intestinal walls. It is specifically formulated for the control and reduction of the symptoms related to diarrheal events of different aetiologies in adults and children. TASECTAN® AF is a class IIa medical device and complies with the Essential Requirements of Directive 93/42/EEC and subsequent amendments (CE 0476, Noventure SL). For more information about our products click here: http://noventure.com/products

Read more

Launch of TASECTAN® AF in Denmark

Noventure is glad to announce the launch of TASECTAN® AF in Denmark by its partner company Pharmaforce, thus setting a record time-to-market, after Noventure granted Pharmaforce exclusive distribution right for Tasectan® AF in the Nordic markets last April. Tasectan® AF is intended to restore the physiological functions of the intestinal walls. It is specifically formulated for the control and reduction of the symptoms related to diarrheal events of different aetiologies in adults and children.

Read more

Let's meet in..

2023, Mar 10

EAU 2023

Read more

2023, May 03

EWMA 2023

Read more

2023, May 09

Vitafoods 2023

Read more

2023, May 17

ESPGHAN 2023

Read more